Volcano Capital
3 Columbus Circle, 15th Floor, New York, NY, 10019, United States
Overview
Volcano Capital is a healthcare venture capital that provides funding and operational expertise to help entrepreneurs grow their healthcare businesses. It invests in health care companies across a variety of asset classes including venture capital, public equities, and debt. Volcano Capital was founded in 2009 and is headquartered in New York.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Health Care
- Medical Device
- Venture Capital
Investment portfolio
- Mercator MedSystems
Led · Series B · May 2013
Mercator MedSystems is a medical device company based in Emeryville, CA, focused on the clinical and commercial development of proprietary catheter-based micro-infusion technologies. Its products include the Bullfrog® Micro-Infusion Device for intravascular delivery and the Blowfish® Transbronchial Micro-Infusion Catheter for airway delivery. The company is developing clinical applications in peripheral and coronary artery disease, cancer, hypertension and cardiac regeneration. Led by CEO Trent Reutiman, Mercator holds FDA clearance and CE marking for its technologies. The company intends to use new funds to further advance the clinical development of its micro-infusion catheter systems. Mercator MedSystems develops catheter-guided micro-infusion systems, including the Cricket™ and Bullfrog® Micro-Infusion devices, for targeted delivery of drugs and biologics to treat conditions such as cardiovascular disease, oncology, hypertension and PAD. The company spun out of the University of California, Berkeley in 2000 and is based in San Leandro, CA. It is led by CEO Thomas M. Loarie and CSO Kirk P. Seward, Ph.D. Mercator intends to use the recent funding to initiate sales of its devices in Europe, the United States and Australia. The company will also use proceeds to support clinical validation of its platform to treat peripheral artery disease. Mercator recently closed a $6.5M Series B financing to fund these commercial and clinical efforts.
Team
No current team members are available.